FDA Granted Fast Track Designation for Genervon’s Breakthrough Biotechnology Multi-Target #ALS Drug GM604 Expediting Drug Approval Process

See on Scoop.itInteresting Innovation

In a huge victory for ALS sufferers, FDA granted Genervon Biopharmaceuticals a fast track designation for its first in class highly effective multi-target master regulator biotechnology drug GM604 for ALS.

See on www.heraldonline.com